We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented...
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class...
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.14 | -3.64583333333 | 3.84 | 4.12 | 3.56 | 27557 | 3.82844909 | CS |
| 4 | -0.99 | -21.1087420043 | 4.69 | 5.83 | 3.42 | 47270 | 4.33119847 | CS |
| 12 | 0.61 | 19.7411003236 | 3.09 | 5.83 | 3.09 | 61032 | 4.29195018 | CS |
| 26 | 0.74 | 25 | 2.96 | 5.83 | 2.62 | 104511 | 3.65337245 | CS |
| 52 | -2.78 | -42.9012345679 | 6.48 | 6.88 | 1.66 | 125210 | 3.68953721 | CS |
| 156 | -37.07 | -90.924699534 | 40.77 | 45.33 | 1.66 | 188103 | 13.28228983 | CS |
| 260 | -22.06 | -85.6366459627 | 25.76 | 95.375 | 1.66 | 191650 | 20.80077997 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
